Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report

被引：88

作者：

Hoyle, N. ^{[1
]}

Zhvaniya, P. ^{[1
]}

Balarjishvili, N. ^{[2
]}

Bolkvadze, D. ^{[2
]}

Nadareishvili, L. ^{[1
]}

Nizharadze, D. ^{[1
]}

Wittmann, J. ^{[3
]}

Rohde, C. ^{[3
]}

Kutateladze, M. ^{[2
]}

机构：

[1] Eliava Phage Therapy Ctr, Tbilisi, Georgia

[2] Eliava Inst Bacteriophages Microbiol Virol, Tbilisi, Georgia

[3] Leibniz Inst DSMZ German Collect Microorganisms &, Braunschweig, Germany

来源：

RESEARCH IN MICROBIOLOGY | 2018年 / 169卷 / 09期

关键词：

Bacteriophage; Phage therapy; Cystic fibrosis; Achromobacter xylosoxidans; Antibiotic resistance; Respiratory infection; BACTERIOPHAGES; SURVIVAL; OUTCOMES;

D O I：

10.1016/j.resmic.2018.05.001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Respiratory infections can lead to serious complications in CF patients, especially when infected with antibiotic resistant bacteria. Alternative treatments for these infections are being sought out to help address this problem. We present a clinical case of a cystic fibrosis (CF) patient, with multi-drug resistant (MDR) Achromobacter xylosoxidans chronic lung infection who was successfully managed with bacteriophage therapy. (C) 2018 Published by Elsevier Masson SAS on behalf of Institut Pasteur.

引用

页码：540 / 542

页数：3

共 50 条

[1] A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient
Lebeaux, David
Merabishvili, Maia
Caudron, Eric
Lannoy, Damien
Van Simaey, Leen
Duyvejonck, Hans
Guillemain, Romain
Thumerelle, Caroline
Podglajen, Isabelle
Compain, Fabrice
Kassis, Najiby
Mainardi, Jean-Luc
Wittmann, Johannes
Rohde, Christine
Pirnay, Jean-Paul
Dufour, Nicolas
Vermeulen, Stefan
Gansemans, Yannick
Van Nieuwerburgh, Filip
Vaneechoutte, Mario
[J]. VIRUSES-BASEL, 2021, 13 (01):
[2] Hypermutation as an Evolutionary Mechanism for Achromobacter xylosoxidans in Cystic Fibrosis Lung Infection
Veschetti, Laura
Sandri, Angela
Johansen, Helle Krogh
Lleo, Maria M.
Malerba, Giovanni
[J]. PATHOGENS, 2020, 9 (02):
[3] Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid
Llorca Otero, Laura
Giron Moreno, Rosa
Buendia Moreno, Buenaventura
Valenzuela, Claudia
Guiu Martinez, Alba
Alarcon Cavero, Teresa
[J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2016, 34 (03): : 184 - 187
[4] Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
A. Lambiase
M. R. Catania
M. del Pezzo
F. Rossano
V. Terlizzi
A. Sepe
V. Raia
[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2011, 30 : 973 - 980
[5] Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis
Marsac, Charlotte
Berdah, Laura
Thouvenin, Guillaume
Sermet-Gaudelus, Isabelle
Corvol, Harriet
[J]. ERJ OPEN RESEARCH, 2021, 7 (02)
[6] Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
Lambiase, A.
Catania, M. R.
del Pezzo, M.
Rossano, F.
Terlizzi, V.
Sepe, A.
Raia, V.
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (08) : 973 - 980
[7] Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients;: a retrospective case control study
Hansen, Christine Ronne
Pressler, Tacjana
Hoiby, Niels
Gormsen, Magdalena
[J]. JOURNAL OF CYSTIC FIBROSIS, 2006, 5 (04) : 245 - 251
[8] RituximabDisseminated Achromobacter xylosoxidans infection?: case report
[J]. Reactions Weekly, 2013, 1435 (1) : 23 - 23
[9] Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis
Talbot, Nick P.
Flight, William G.
[J]. PAEDIATRIC RESPIRATORY REVIEWS, 2016, 20 : 27 - 29
[10] ACHROMOBACTER XYLOSOXIDANS INFECTION RATE AND CLINICAL OUTCOMES IN A CYSTIC FIBROSIS CENTER
Duval, M. A.
Maxa, K.
Sedor, J.
[J]. PEDIATRIC PULMONOLOGY, 2013, 48 : 331 - 331

← 1 2 3 4 5 →